• Inify Laboratories on Oct. 28, 2026, reported diagnostic review findings already presented at the European Congress of Pathology in Stockholm.
• External pathologists reviewed nearly 2,000 patient cases; no revisions were considered sufficient to change a potential treatment decision.
• Research with Karolinska Institutet, also presented at the congress, suggested an AI-identified tumor growth pattern could indicate aggressive disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INIFY Laboratories AB published the original content used to generate this news brief via Cision (Ref. ID: 202610280300BITN____UKPR__SV_20261027-BIT-0781-0) on October 28, 2026, and is solely responsible for the information contained therein.